Private Equity

Following a record year, Fingerpaint Group elevates veteran insiders to top roles, proving its culture-first succession strategy is a blueprint for success.

A new lineup of seasonings taps into global, comfort, and sweet-heat trends to help meat processors navigate a volatile and competitive market.

As CFO Jim Kelly retires, Orbia promotes Cristian Capellino, the architect of its finance modernization, ensuring strategic continuity and focus on growth.

The deal merges local surveying expertise with national geospatial power, reshaping the infrastructure services landscape in fast-growing Central Texas.

Black Bear Sports Group promises multi-million dollar upgrades for two local ice arenas, but its controversial business model raises concerns for families.

Amid a surge in MedTech M&A, Piper Sandler appoints 25-year veteran Aamer Naseer to steer its life sciences outsourcing and B2B technology groups.

Facing financial headwinds, Mint Inc. pivots into the high-stakes world of AI, unveiling the FLOKI Minibot M1, a personalized companion for Asia.

Struggling biotech Jupiter Neurosciences presents its Parkinson's drug to elite investors at Mar-a-Lago, betting its hybrid business model can win funding.

Facing DEI headwinds, the Diversity Action Alliance unveils a new strategy and its most diverse board yet, reframing inclusion as a business imperative.

Backed by 1.2M citizens and 8 former world leaders, the 'My Voice, My Choice' initiative puts European democracy and reproductive rights at a crossroads.

Advantage Solutions overhauls its board, adding heavyweights in capital markets and commercial strategy to navigate a pivotal transformation and retail industry shifts.

With funding from a mining giant, Finlay Minerals' latest results identify three major drill-ready copper-gold targets in BC's Toodoggone district.

With legendary geologist Doug Kirwin and Latin America expert Carlos Velásquez on board, Terra Rossa is set to unlock its high-grade Vetas gold project.

As Evolus presents at a key healthcare conference, investors watch to see if its new filler line and digital strategy can deliver on bold promises.

Investors sue Corcept Therapeutics, claiming the company hid FDA warnings about its key drug, relacorilant, before a 50% stock price collapse.

As Aura presents its precision oncology pipeline at key conferences, investors will weigh the promise of its lead drug against a challenging financial landscape.

As Kimco Realty prepares to present at the Raymond James conference, investors are watching for insights into its grocery-anchored retail strategy.

With its new HAE drug EKTERLY® smashing revenue forecasts, KalVista heads to key conferences where investors will scrutinize its path to profitability.

U.S. Energy Corp. unveils an ambitious plan to merge helium, oil, and carbon capture, but can this small-cap company deliver on its big promises?

The fashion giant's revenue grew 11% in 2025, but net income fell sharply due to acquisition costs, tariffs, and a murky outlook for 2026.